Dharmapuri, India

Ramprasad Murugan

This inventor holds 1 USPTO granted patent. Top assignee: Glenmark Specialty S.a.. Active years: 2020.


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Ramprasad Murugan

Introduction

Ramprasad Murugan is an accomplished inventor based in Dharmapuri District, India. He has made significant contributions to the field of medicine, particularly in the development of nebulization compositions for respiratory diseases. His work is characterized by a commitment to improving treatment options for patients suffering from inflammatory or obstructive airway diseases.

Latest Patents

One of Ramprasad Murugan's notable patents is for nebulizable compositions of tiotropium and formoterol. This patent focuses on a composition designed for nebulization, which combines tiotropium and formoterol to effectively treat inflammatory or obstructive airway diseases. The patent also outlines a process for preparing this innovative composition, showcasing his expertise in pharmaceutical formulations.

Career Highlights

Ramprasad currently works at Glenmark Specialty S.A., where he continues to contribute to advancements in medical treatments. His role at the company allows him to collaborate with other professionals in the field, enhancing the development of effective therapeutic solutions.

Collaborations

Some of his coworkers include Ulhas R. Dhuppad and Mahadeorao S. Rase. Their collaboration fosters a dynamic environment for innovation and research, furthering the impact of their collective work in the pharmaceutical industry.

Conclusion

Ramprasad Murugan's contributions to the field of medicine through his innovative patents and collaborative efforts highlight his dedication to improving healthcare solutions. His work exemplifies the importance of innovation in addressing critical health challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…